Turvey Park

Researchers are evaluating the effectiveness of a personalized stepped, multidisciplinary intervention delivered through a virtual multimodal rehabilitation hub for adults undergoing colorectal cancer surgery. The main goal is to reduce postoperative complications within 30 days after surgery compared to usual care. The study also aims to assess differences in quality of life, days spent at home after surgery, quality of recovery, cost-effectiveness, and implementation metrics over time. Participants will be randomly assigned to either the intervention group, which receives usual care plus tailored exercise, nutritional, psychological, nursing support, and group peer support delivered virtually before and after surgery, or the control group, which receives usual care alone. The interventions frequency and duration are adjusted based on individual needs and can last up to 12 months post-surgery. If needed, participants will be provided with devices and internet access to engage in virtual sessions. During the study, participants will be screened and consented before surgery, undergo baseline assessments, and be monitored regularly using standardized tools to evaluate recovery, quality of life, and days at home up to one year after surgery. Safety and data quality will be overseen by an independent monitoring board. The total study duration is approximately five years, and patient-reported outcomes will be carefully documented throughout.

Researchers are evaluating treatments for community-acquired pneumonia CAP, especially in patients admitted to intensive care units ICUs. This trial also adapts to study treatments for respiratory pandemics like COVID-19. The goal is to determine which treatment strategies improve outcomes for patients with severe pneumonia, using a flexible, ongoing approach that can test multiple therapies simultaneously and update as new information becomes available. Participants receive different treatment strategies based on random assignment to study groups. Treatments include various antibiotics, steroids, antivirals, immune modulators, anticoagulation methods, and ventilation strategies. Some treatment options have been closed to recruitment, reflecting the trials adaptive nature. The trial includes several domains targeting specific infections such as influenza and COVID-19, with dosing and duration guided by clinical practice and local guidelines. During the study, participants are monitored closely with assessments including survival up to 90 days, days alive without organ support in ICU, ICU and hospital length of stay, ventilator-free days, organ failure-free days, and quality of life up to 6 months. Researchers collect detailed data on patient outcomes, organ support needs, and hospital discharge status. The study runs until February 2028, with ongoing evaluation to improve pneumonia treatment strategies in ICU settings and during respiratory pandemics.

Researchers are evaluating whether increasing the use of finger-stick point-of-care testing for hepatitis C virus HCV infection improves diagnosis and treatment rates. The study focuses on people at risk for HCV infection, recruited from various settings such as drug treatment clinics, needle and syringe programs, homelessness services, mental health services, prisons, and mobile outreach. This observational cohort study aims to address challenges in HCV elimination caused by reduced treatment uptake and barriers in current diagnostic pathways. Participants will attend a single visit to receive point-of-care HCV testing using finger-stick methods. Testing includes rapid HCV antibody tests, and if positive, further HCV RNA testing is performed to detect active infection. Those with detectable HCV RNA will be linked to standard care for further assessment and treatment outside the study. Participants will complete a self-administered survey during the visit. No treatment is provided as part of this study. During the study, researchers will measure how many participants with active HCV infection start treatment within 12 weeks after testing. They will also evaluate acceptance of testing, prevalence of active infection, treatment initiation timing, treatment completion, and virus clearance rates up to 52 weeks following testing. Data from surveys will be linked to administrative records to assess long-term health outcomes. Participation involves only one study visit for testing and survey completion.